Antiviral therapies for cytomegalovirus in solid-organ transplantation

Transplantation

Volumn 84, Issue 6 SUPPL., 2007, Pages

  Pescovitz, Mark D ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; BENZIMIDAVIR; CIDOFOVIR; CYTOMEGALOVIRUS VACCINE; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; VALACICLOVIR; VALGANCICLOVIR;

ANTIVIRAL THERAPY; AREA UNDER THE CURVE; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG COST; DRUG DOSE REDUCTION; DRUG FORMULATION; DRUG MECHANISM; EPSTEIN BARR VIRUS; GRAFT REJECTION; HERPES VIRUS INFECTION; HUMAN; INCIDENCE; LEUKOPENIA; LYMPHOPROLIFERATIVE DISEASE; MORTALITY; NEPHROTOXICITY; NEUTROPENIA; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL RATE; TASTE DISORDER; UNSPECIFIED SIDE EFFECT; VIREMIA; VIRUS DETECTION; VIRUS REPLICATION;

EID: 34748860306     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000280538.30629.99     Document Type: Conference Paper

References (48)

1. Gane E, Saliba F, Valdecasas GJ, et al. Randomized trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet 1997; 350: 1729.
2. Kanj SS, Sharara AI, Clavien PA, Hamilton JD. Cytomegalovirus infection following liver transplantation: Review of the literature. Clin Infect Dis 1996; 22: 537.
3. Singh N. Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: A call to heed the mounting evidence. Clin Infect Dis 2005; 40: 704.
4. Griffiths PD. The 2001 Garrod lecture. The treatment of cytomegalovirus infection. J Antimicrob Chemother 2002; 49: 243.
5. Pescovitz MD. Benefits of cytomegalovirus prophylaxis in solid organ transplantation. Transplantation 2006; 82: S4.
6. Pescovitz MD. Valganciclovir: What is the status in solid organ transplantation? Future Virol 2006; 1: 147.
7. Cytomegalovirus. Am J Transplant 2004; 4(Suppl. 10): 51.
8. Huurman VA, Kalpoe JS, van de LP, et al Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients. Diabetes Care 2006; 29: 842.
9. Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005; 5: 218.
10. Opelz G, Dohler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004; 4: 928.
11. Ricart MJ, Malaise J, Moreno A, Crespo M, Fernandez-Cruz L. Cytomegalovirus: Occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation. Nephrol Dial Transplant 2005; 20 Suppl 2: ii25.
12. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomized controlled trials. Lancet 2005; 365: 2105.
13. Funch DP, Walker AM, Schneider G, Ziyadeh NJ, Pescovitz MD. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 2005; 5: 2894.
14. Boobes Y, Al Hakim M, Dastoor H, Bernieh B, Abdulkhalik S. Late cytomegalovirus disease with atypical presentation in renal transplant patients: Case reports. Transplant Proc 2004; 36: 1841.
15. Shibolet O, Ilan Y, Kalish Y, et al. Late cytomegalovirus disease following liver transplantation. Transpl Int 2003; 16: 861.
16. Slifkin M, Tempesti P, Poutsiaka DD, Snydman DR. Late and atypical cytomegalovirus disease in solid-organ transplant recipients. Clin Infect Dis 2001; 33: E62.
17. Kruger RM, Paranjothi S, Storch GA, Lynch JP, Trulock EP. Impact of prophylaxis with cytogam alone on the incidence of CMV viremia in CMV-seropositive lung transplant recipients. J Heart Lung Transplant 2003; 22: 754.
18. Metselaar HJ, Balk AH, Mochtar B, Rothbarth PH, Weimar W. Cytomegalovirus seronegative heart transplant recipients. Prophylactic use of anti-CMV immunoglobulin. Chest 1990; 97: 396.
19. Bonaros NE, Kocher A, Dunkler D, et al. Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients. Transplantation 2004; 77: 890.
20. Gutierrez CA, Chaparro C, Krajden M, Winton T, Kesten S. Cytomegalovirus viremia in lung transplant recipients receiving ganciclovir and immune globulin. Chest 1998; 113: 924.
21. Biron KK. Antiviral drugs for cytomegalovirus diseases. Antiviral Res 2006; 71: 154.
22. Valcyte package insert. 2003. Data File.
23. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611.
24. Gabardi S, Magee CC, Baroletti SA, Powelson JA, Cina JL, Chandraker AK. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: A single-center, retrospective analysis. Pharmacotherapy 2004; 24: 1323.
25. Gruber SA, Garnick J, Morawski K, et al. Cytomegalovirus prophylaxis with valganciclovir in African-American renal allograft recipients based on donor/recipient serostatus. Clin Transplant 2005; 19: 273.
26. Keven K, Basu A, Tan HP, et al. Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas-kidney transplantation under antibody preconditioning. Transplant Proc 2004; 36: 3107.
27. Park JM, Lake KD, Arenas JD, Fontana RJ. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients. Liver Transpl 2006; 12: 112.
28. Wiltshire H, Paya CV, Pescovitz MD, et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 2005; 79: 1477.
29. Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000; 44: 2811.
30. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070.
31. Vathsala A, Ona ET, Tan SY, et al. Randomized trial of Alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 2005; 80: 765.
32. Vincenti F, Mendez R, Curtis J, et al. A multicenter, prospective study of C2-monitored cyclosporine microemulsion in a U.S. population of de novo renal transplant recipients. Transplantation 2005; 80: 910.
33. Clark BS, Chang IF, Karpen SJ, et al. Valganciclovir for the prophylaxis of cytomegalovirus disease in pediatric liver transplant recipients. Transplantation 2004; 77: 1480.
34. Danziger-Isakov LA, Faro A, Sweet S, et al. Variability in standard care for cytomegalovirus prevention and detection in pediatric lung transplantation: Survey of eight pediatric lung transplant programs. Pediatr Transplant 2003; 7: 469.
35. Pescovitz MD, Brook B, Jindal RM, Leapman SB, Milgrom ML, Filo RS. Oral ganciclovir in pediatric transplant recipients: A pharmacokinetic study. Clin Transplant 1997; 11: 613.
36. Pescovitz MD, Jain A, Robson R, Mulgoankar S, Freeman R, Bouw MR. Establishing pharmacokinetic bioequivalence of valganciclovir oral solution versus the tablet formulation. Transplant Proc (in press).
37. Jacobson MA, Sinclair E, Bredt B, et al. Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12. Vaccine 2006; 24: 5311.
38. Plotkin SA, Higgins R, Kurtz JB, et al. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 1994; 58: 1176.
39. Gonczol E, Plotkin S. Development of a cytomegalovirus vaccine: Lessons from recent clinical trials. Expert Opin Biol Ther 2001; 1: 401.
40. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352: 2271.
41. Lu H, Thomas S. Maribavir. Curr Opin Investig Drugs 2004; 5: 898.
42. Chong AS, Zeng H, Knight DA, et al. Concurrent antiviral and immunosuppressive activities of leflunomide in vivo. Am J Transplant 2006; 6: 69.
43. Sudarsanam TD, Sahni RD, John GT. Leflunomide: a possible alternative for gangciclovir sensitive and resistant cytomegalovirus infections. Postgrad Med J 2006; 82: 313.
44. Kaplan MJ. Leflunomide. Curr Opin Investig Drugs 2001; 2: 222.
45. Avery RK, Bolwell BJ, Yen-Lieberman B, et al. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection. Bone Marrow Transplant 2004; 34: 1071.
46. Ehlert K, Groll AH, Kuehn J, Vormoor J. Treatment of refractory CMV-infection following hematopoietic stem cell transplantation with the combination of foscarnet and leflunomide. Klin Padiatr 2006; 218: 180.
47. John GT, Manivannan J, Chandy S, Peter S, Jacob CK. Leflunomide therapy for cytomegalovirus disease in renal allograft recepients. Transplantation 2004; 77: 1460.
48. John GT, Manivannan J, Chandy S, et al. A prospective evaluation of leflunomide therapy for cytomegalovirus disease in renal transplant recipients. Transplant Proc 2005; 37: 4303.